The adolescence of cancer immunotherapy: from a  difficult childhood to a pillar of modern anticancer therapy
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 24, 2018 Category: Cancer & Oncology Source Type: research

Current and future developments of immunotherapy in lung cancer
This article summarizes the current evidence for ICIs in early and advanced NSCLC as well as in SCLC. Furthermore, current data and ongoing clinical trials on combination therapies are discussed as well as challenges of immunotherapy in lung cancer patients. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 23, 2018 Category: Cancer & Oncology Source Type: research

ASH 2017: highlights in chronic myeloid leukemia
SummaryDespite remarkable achievements in the management of chronic myeloid leukemia (CML), there remain a  number of challenges in the field. At the American Society of Hematology (ASH) Meeting 2017 several presentations addressed current problems around the topics CML stem cells, progression of CML into blast crisis (BC), and personalized treatment. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 23, 2018 Category: Cancer & Oncology Source Type: research

Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
SummaryPatients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemotherapy, optimal sequencing of treatments, treatment guidance by means of predictive biomarkers, and value-based judgements of treatments. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 18, 2018 Category: Cancer & Oncology Source Type: research

Post SABCS local therapy and radiology
SummaryThis year there were three interesting oral presentations and several posters presenting important new data regarding local therapy (surgery and radiotherapy) as well as radiological aspects. This minireview is a  personal view of the clinically most relevant data in this respect with the following conclusions: A micrometastasis is no indication for axillary dissection. The number of involved sentinel lymph nodes predicts non-sentinel lymph node metastasis and should be taken into account regarding omittin g axillary dissection. Neoadjuvant chemotherapy reduces the risk of non-sentinel lymph node metastasi...
Source: Memo - Magazine of European Medical Oncology - May 15, 2018 Category: Cancer & Oncology Source Type: research

Pulmonary mass: never judge a  book by its cover
ConclusionLymphomatoid granulomatosis (LYG) is a rare pulmonary disease, which should be included in the differential diagnosis of ‘a pulmonary mass’. This case emphasizes the need for tissue acquisition. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 23, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  1: Bone marrow diagnostics in hemato-oncological diseases
SummaryProliferation or reduction of one or more cell lines in the peripheral blood count, occurrence of cells not normally found in the peripheral blood (e.g., blast cells, red precursors), suspicious laboratory findings (e.g., paraproteins, free light chains), lymphadenopathy of unclear origin, or other clinical signs (e.g., fever, B ‑symptoms, bone pain) are indicators of hematologic disease.The following methods can be used either to establish a  diagnosis or to suspect a diagnosis even based on analysis of peripheral blood: cytological cell differentiation, interpretation of cell morphology, laboratory dia...
Source: Memo - Magazine of European Medical Oncology - April 13, 2018 Category: Cancer & Oncology Source Type: research

Hemoglobinopathies —genetically diverse, clinically complex, and globally relevant
SummaryHemoglobinopathies represent the most frequent monogenic disorders worldwide. Migration during recent years led to a  profoundly increasing number of patients in countries where the indigenous population has not been affected. This short review will give an overview on etiology, pathogenesis, clinical features, diagnostics, and treatment of the most relevant hemoglobinopathies, i.e., the thalassemias and sickle c ell disease. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 13, 2018 Category: Cancer & Oncology Source Type: research

Laboratory diagnostics in hematology —a new “Educational” series
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 13, 2018 Category: Cancer & Oncology Source Type: research

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 27, 2018 Category: Cancer & Oncology Source Type: research

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms
SummaryPhiladelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by mutations in genes, such asJAK2V617F,JAK2 exon12 gene andMPL. With respect to MPN-associated subclasses, each of these disorders has a  different allele burden during disease treatment. Up to now, several studies have been conducted on the relationship between allele burden with specific MPN-associated phenotypic features, prognosis and disease progression. It seems that finding such a correlation would be a great ...
Source: Memo - Magazine of European Medical Oncology - March 22, 2018 Category: Cancer & Oncology Source Type: research

Pitfalls in the radiological response  assessment of immunotherapy
SummaryImmunotherapies comprise of a  class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial c arcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and ...
Source: Memo - Magazine of European Medical Oncology - March 21, 2018 Category: Cancer & Oncology Source Type: research

Indolent lymphoma at ASH (American Society of Hematology) 2017: maintenance revisited
SummaryAt the last ASH (American Society of Hematology) meeting a  new prognostic tool for follicular lymphoma (FL), based on the patient cohort of the PRIMA trial (PRIMA-PI, Primary Rituximab and Maintenance-Prognostic Index), was presented. The 10-year update of the PRIMA trial confirms the continuous advantage in progression-free survival of rituximab maintena nce after R‑CHOP induction without new safety signals. Similarly rituximab maintenance is beneficial in FL after first-line chemoimmunotherapy with rituximab–bendamustine. Currently checkpoint inhibitors are under investigation in different treatment ...
Source: Memo - Magazine of European Medical Oncology - March 21, 2018 Category: Cancer & Oncology Source Type: research

PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients
SummaryUntil recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/cisplatin has been established as an alternative to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The advent of checkpoint inhibitors (CPI) revolutionized the care of these patients, transforming a unanimously deadly disease into one with hope through sustained diseas...
Source: Memo - Magazine of European Medical Oncology - March 8, 2018 Category: Cancer & Oncology Source Type: research

In need of special care: adolescent and young adult patients with cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 2, 2018 Category: Cancer & Oncology Source Type: research

APPLY: A  prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania
In this study, 497 patients with a  mean age of 60.6 years were analyzed. Most patients (80.7%) were initiated on darbepoetin alfa at a Hb of 9–11 g/dL, congruent with recommendations. The median Hb increased by 0.9 g/dL between baseline and week 12. Hb target achievement was higher among patients treated according to guidel ines than those initiated at Hb 
Source: Memo - Magazine of European Medical Oncology - March 2, 2018 Category: Cancer & Oncology Source Type: research

Revival of anti-angiogenic therapies in cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 27, 2018 Category: Cancer & Oncology Source Type: research

Targeting angiogenesis in lung cancer
SummaryAngiogenesis inhibition is a  promising way to inhibit and eradicate cancer. Many attempts have been made to use this tool for the treatment of lung cancer. Some success has been reported, and antiangiogenic drugs are actively being investigated in combination with other types of anticancer treatments. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Antiangiogenic therapies in ovarian cancer
SummaryAntiangiogenic compounds were the first active targeted agents implemented in the treatment of ovarian cancer. Bevacizumab and tyrosine kinase inhibitors such as pazopanib, nintedanib and cediranib target the VEGF pathway, while trebananib was developed as an inhibitor of the angiopoietin pathway. All these compounds have been extensively evaluated and, in this review, we provide a  structured overview of the randomized trials that have been performed in both primary and relapsed ovarian cancer. From this data, it is evident that antiangiogenic therapy has its place in ovarian cancer. If not during first-line t...
Source: Memo - Magazine of European Medical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer
SummaryThe STAMPEDE and CHAARTED trials brought about practice-changing innovation in the management of patients with metastatic, castration-naive prostate cancer (CNPC). These trials reported a  clinically meaningful overall survival benefit of chemohormonal therapy consisting of the addition of six cycles of docetaxel to androgen deprivation therapy (ADT) in high-volume metastatic CNPC. Moreover, the STAMPEDE study also transformed our thinking about conducting clinical trials through it s adaptive, multigroup, multistage trial design. With the recent results of the LATITUDE trial and publication of another STAMPEDE...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
ConclusionPleural effusion carries a  differential diagnosis which may include malignancy but is commonly thought to be less specific to multiple myeloma but should still remain in the differential diagnosis. To our knowledge, this is the first case of myelomatous pleural effusion (MPE) that was reported after multiple relapses of MM. MPE is a very rare complication of MM, and its presence is a strong indicator of imminent mortality and need for comfort care in case of multiple relapses. End-stage pleural effusion in MM in the setting of proteasome inhibitor adds more therapeutic and diagnostic challenges. (...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
SummaryThe treatment of newly diagnosed multiple myeloma has changed dramatically over the past 20  years, from near uniform application of chemotherapy to a patient performance status- and risk-based approach. Furthermore, initiation of treatment criteria have evolved from a pure end-organ damage-based definition to include risk factors of transformation to frank myeloma. Besides, the mainly cytogenetically defined Multiple Myeloma (MM) risk status, transplant eligibility of patients still serves primarily to allocate patients within a rational treatment algorithm.While all transplant-eligible MM patie...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood
SummarySurvival after childhood cancer has improved substantially; therefore, the number of childhood cancer survivors is increasing. This growing population of childhood cancer survivors, however, is at risk of a  spectrum of adverse health outcomes. Unfortunately, until now, there was a lack of comprehensive follow-up recommendations. The purpose of this article is to provide information on recently developed harmonized evidence-based guidelines on surveillance investigations to screen for the early detec tion of breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian failure in childhood canc...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Report from the WCLC 2017 Congress, Yokohama, 15th –18th October, 2017
Correction to:memo 2017https://doi.org/10.1007/s12254-017-0381-xUnfortunately, the title of this article was published incorrect.The correct title is: Report from the WCLC 2017 Congress, Yokohama, 15th –18th October, 2017.The original article has been … (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

ESMO 2017 —my personal highlights
This article is not intended to be a  comprehensive review of all highlights presented at the recent ESMO Annual Meeting, but rather a summary from a personal point of view in three very different fields of oncology. Breast cancer and lung cancer are traditionally in the focus of interest, and again, relevant new data were presented . The third part of this overview is focused on novel treatment strategies in malignant lymphoma, a field that is also quickly evolving and traditionally underrepresented at meetings dealing with solid cancers. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 16, 2018 Category: Cancer & Oncology Source Type: research

Anti-angiogenic therapies in  brain metastases
SummaryBrain metastases are a  major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition using anti-angiogenic therapy might therefore be an experimental promising prevent ive as well as therapeutic approach. The current review will summarize the current available data on the efficacy of neo-angiogenic therapies in patients with brain metastases. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 2, 2018 Category: Cancer & Oncology Source Type: research

Role of complement in the pathogenesis of thrombotic microangiopathies
SummaryThrombotic microangiopathies (TMAs) are rare but life-threatening disorders characterized by microvascular hemolytic anemia and acute thrombocytopenia with or without organ damage. The term TMA covers various subgroups of diseases, the pathogenesis of which is briefly summarized in this review. As highlighted here, complement activation may represent an important amalgamating process in all of these conditions, since it is able to link together activation and damage of multiple involved cell types, such as endothelial cells, platelets, and neutrophils. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 17, 2018 Category: Cancer & Oncology Source Type: research

Report from the WCLC 2017 Congress, Yokohama, 15th –18th October, 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 8, 2018 Category: Cancer & Oncology Source Type: research

Local therapy of stage IV renal cell cancer: a case report
SummaryThis mini-review and case report demonstrates how systemic and local treatments work synergistically for patients with metastatic renal cell carcinoma (mRCC). Although new targeted and immunotherapies have revolutionized the treatment armamentarium of mRCC and dramatically improved patients ’ prognosis, local treatment remains an important part of therapy. Here, we report on a patient who benefitted enormously from the combination and interaction of both therapeutic approaches, and we summarize the literature and guidelines that supported our treatment decisions in this case. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 8, 2018 Category: Cancer & Oncology Source Type: research

Report from the WCLC 2017 Congress, Yokohama, 8th –12th September, 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 8, 2018 Category: Cancer & Oncology Source Type: research

memo —publisher’s report 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 5, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in the neoadjuvant treatment for breast cancer
SummaryA  combination of anthracyclines and taxanes remains the standard of care for neoadjuvant chemotherapy (NACT) resulting in increased breast conservation rate (BCR) and decreased recurrence rate [1]. Whether pathological complete response (pCR) could be an appropriate surrogate parameter for long-term survival is still a  matter of debate. In patients with triple-negative breast cancer (TNBC) and HER2-positive breast cancer (BC), a six to nine times higher risk for relapse has been reported if no pCR was achieved [2,3]. Within these aggressive subtypes the strongest association between pCR and long-ter...
Source: Memo - Magazine of European Medical Oncology - December 22, 2017 Category: Cancer & Oncology Source Type: research

My burning issues in TKI therapy and treatment-free remission in CML
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 21, 2017 Category: Cancer & Oncology Source Type: research

ASCO 2017 —highlights of gynecological cancer
SummaryAt this year ’s ASCO annual meeting several important studies in the field of gynecological cancer were presented. Here we report a personal selection of the most interesting and clinically relevant data. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 5, 2017 Category: Cancer & Oncology Source Type: research

Antiangiogenic therapies in urogenital malignancies
SummaryThe use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a &nbs...
Source: Memo - Magazine of European Medical Oncology - December 4, 2017 Category: Cancer & Oncology Source Type: research

ASCO update: lung cancer
This article provides a brief overview of the highlights presented at the ASCO (American Society of Clinical Oncology) annual meeting this year in Chicago. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2017 Category: Cancer & Oncology Source Type: research

Aggressive lymphoma 2016: revision of the WHO classification
SummaryAggressive lymphomas are a  heterogeneous group of malignancies reflecting clinical, biological and pathological diversity. Diffuse large B‑cell lymphoma is the most common histological subtype and therefore will constitute the key aspect in this article. This lymphoma affects patients of all age groups with wide range pre sentations concerning localization, morphology and molecular mechanisms. The median age at presentation is about 60 years with a slight male preponderance. Up to 50% of patients present with advanced disease. About 70% of these lymphomas occur nodal, about 30% extranodal, the most...
Source: Memo - Magazine of European Medical Oncology - November 30, 2017 Category: Cancer & Oncology Source Type: research

ASCO update on lymphoma
SummaryAbstracts concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 24, 2017 Category: Cancer & Oncology Source Type: research

The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling
SummaryPersonalized medicine is rapidly changing the daily routine for the diagnostic work-up and treatment of cancer patients. Several clinical studies and programs are ongoing worldwide to implement personalized anticancer therapies particularly for relapsed/refractory malignancies. On 28  October 2016, the first meeting of the Austrian Expert Panel for Molecular Cancer Profiling was held in Salzburg with the purpose to identify clinical studies and registry programs focusing on comprehensive molecular tumor profiling and personalized cancer therapies in Austria. Representatives of the four Austrian academic ce...
Source: Memo - Magazine of European Medical Oncology - November 22, 2017 Category: Cancer & Oncology Source Type: research

Revival of anti-angiogenic therapies in cancer —news on an old therapeutic concept
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 16, 2017 Category: Cancer & Oncology Source Type: research

ASCO 2017 —making a difference in cancer care with you
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 15, 2017 Category: Cancer & Oncology Source Type: research

ASCO-update: gastrointestinal tumors
SummaryA multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase  3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before convening for the next meeting in 2018. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 13, 2017 Category: Cancer & Oncology Source Type: research

ASCO 2017: highlights in breast cancer
SummaryAt the 2017 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented and some are deemed as being potentially practice changing. BrighTNess was the first phase  III study to investigate the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative breast cancer; while toxicity was increased in the experimental group, a significantly higher pathologic complete remission (pCR) rate was observed as well suggesting that adding carboplat in to neoadjuvant anthracycline, cyclophosphamide and taxane-containing regimens is efficacious in otherwise healthy pa...
Source: Memo - Magazine of European Medical Oncology - November 13, 2017 Category: Cancer & Oncology Source Type: research

Anti-angiogenic therapies for the treatment of angiosarcoma: a  clinical update
SummaryAngiosarcomas are rare aggressive endothelial tumours, and are associated with a  poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the r esponse to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 7, 2017 Category: Cancer & Oncology Source Type: research

Antiangiogenic therapy in breast cancer
SummaryBased on a  strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth factor rec eptor 2(HER2)-negative breast cancer, the addition of bevacizumab to standard chemotherapy improved consistently progression-free survival (PFS), however, without effect on overall survival (OS). In early breast cancer bevacizumab increased the pathologic complete response rate (pCR) after neoadjuv an...
Source: Memo - Magazine of European Medical Oncology - November 6, 2017 Category: Cancer & Oncology Source Type: research

Next generation sequencing: clinical  applications in solid tumours
SummaryNext generation sequencing (NGS) has unravelled the genetic alterations that underlie the pathogenesis of cancer. It is now becoming integrated into routine clinical diagnostics of malignant tumours. NGS supports diagnosis, identifies therapeutic targets, reveals resistance mechanisms and facilitates disease monitoring. It takes a  central function in the implementation of cancer therapies adapted to the molecular alterations of tumours. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 3, 2017 Category: Cancer & Oncology Source Type: research

Report from the ESMO 2017 Congress, Madrid, 8th –12th September, 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 30, 2017 Category: Cancer & Oncology Source Type: research

Antiangiogenic therapies in colorectal cancer
SummaryAngiogenesis is a  very important step in the development of cancer. Several antiangiogenic biological agents have been studied during the past two decades for the treatment of colorectal cancer, both in adjuvant and metastatic settings. The first and most intensively studied is bevacizumab, a  humanized monoclonal antibody against the vascular endothelial growth factor. Since its approval in 2004, other antiangiogenic agents have been evaluated in clinical trials and some subsequently approved for the treatment of metastatic colorectal cancer such as aflibercept, ram ucirumab, ...
Source: Memo - Magazine of European Medical Oncology - October 25, 2017 Category: Cancer & Oncology Source Type: research

Update on squamous cell carcinoma of the head and neck
SummaryAt the annual ASCO meeting clinically relevant data concerning the management of advanced head and neck cancer that will influence clinical practice in the future were presented.Chemoradiation with high-dose cisplatin remains the mainstay of treatment for patients with locally advanced squamous cell head and neck cancer. Adjuvant therapy with afatinib following chemoradiation failed to show clinical benefit. The combination of bevacizumab with platinum-based chemotherapy improved progression-free survival but did not lead to a  significant difference in overall survival compared to chemotherapy alone. However, ...
Source: Memo - Magazine of European Medical Oncology - October 20, 2017 Category: Cancer & Oncology Source Type: research